Who
William H. Rastetter
Director and Other role
Company insider
Files Form 4 as: Director and Other, Iambic Therapeutics; Director, Dare Bioscience; Director, Fate Therapeutics; Director, Neurocrine Biosciences; Director, Regulus Therapeutics; Director, Illumina; Director, Receptos.
In numbers
- Trades disclosed
- 258
- Buys
- 9
- Sells
- 25
- Bought
- $8.0M
- Sold
- $43.8M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 8 Jun 2006
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | IAM Iambic Therapeuticsoption or derivative | SEC FORM 4 Code A | —40,600 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | DARE Dare BioscienceBiotechnology | SEC FORM 4 Code A | —38,862 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | DARE Dare BioscienceBiotechnology | SEC FORM 4 Code A | —38,862 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,567 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,567 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —3,318 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,318 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,318 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —3,318 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K25,000 at $1.69 | filing |
| 5 May 2026filed 6 May 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K25,000 at $1.69 | filing |
| 5 Nov 2025filed 6 Nov 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 5 Nov 2025filed 6 Nov 2025 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $862K18,000 at $47.89 | filing |
| 5 Nov 2025filed 6 Nov 2025 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $2.7M18,000 at $151.82 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name William H. Rastetter; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.